Tango Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Tango Therapeutics Stock-Based Compensation Growth & History (TNGX)
Tango Therapeutics's stock-based compensation was $26.4M for fiscal 2025.
View full Tango Therapeutics company overviewTango Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $26.4M | −$2.5M | −8.54% |
| 2024 | 2024-12-31 | $28.9M | $9.8M | +51.46% |
| 2023 | 2023-12-31 | $19.1M | $4.8M | +34.08% |
| 2022 | 2022-12-31 | $14.2M | $6.4M | +81.67% |
| 2021 | 2021-12-31 | $7.8M | $6.1M | +344.05% |
| 2020 | 2020-12-31 | $1.8M | — | — |
Tango Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.9M | $10.3M | +157.11% |
| Q1 2026 | 2026-03-31 | $10.8M | $3.5M | +48.82% |
| Q4 2025 | 2025-12-31 | $6.0M | −$1.5M | −19.86% |
| Q3 2025 | 2025-09-30 | $6.6M | −$553,000 | −7.70% |
| Q2 2025 | 2025-06-30 | $6.6M | −$968,000 | −12.84% |
| Q1 2025 | 2025-03-31 | $7.3M | $536,000 | +7.98% |
| Q4 2024 | 2024-12-31 | $7.5M | $2.6M | +52.94% |
| Q3 2024 | 2024-09-30 | $7.2M | $2.3M | +47.70% |
| Q2 2024 | 2024-06-30 | $7.5M | $2.4M | +47.20% |
| Q1 2024 | 2024-03-31 | $6.7M | $2.5M | +59.26% |
| Q4 2023 | 2023-12-31 | $4.9M | $1.1M | +28.90% |
| Q3 2023 | 2023-09-30 | $4.9M | $1.0M | +27.39% |
| Q2 2023 | 2023-06-30 | $5.1M | $1.7M | +49.52% |
| Q1 2023 | 2023-03-31 | $4.2M | $1.0M | +31.64% |
| Q4 2022 | 2022-12-31 | $3.8M | $1.5M | +67.70% |
| Q3 2022 | 2022-09-30 | $3.8M | $385,000 | +11.22% |
| Q2 2022 | 2022-06-30 | $3.4M | $2.2M | +186.37% |
| Q1 2022 | 2022-03-31 | $3.2M | $2.3M | +237.37% |
| Q4 2021 | 2021-12-31 | $2.3M | — | — |
| Q3 2021 | 2021-09-30 | $3.4M | $3.0M | +720.57% |
| Q2 2021 | 2021-06-30 | $1.2M | — | — |
| Q1 2021 | 2021-03-31 | $950,000 | — | — |
| Q3 2020 | 2020-09-30 | $418,000 | — | — |
Tango Therapeutics stock-based compensation trends
Over the last five fiscal years, Tango Therapeutics's stock-based compensation increased from $1.8M to $26.4M, a change of $24.7M. The latest reported quarter, Q2 2026, shows $16.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tango Therapeutics source filings ↗